Mosley Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mosley Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.3K	Buy	+47	New	+$32K	0.01%	296

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mosley Wealth Management's REGN Position: Q2 2026 in Review

Mosley Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 47 shares worth $29.3K. The stake represents 0.01% of the portfolio and ranks #296 among its holdings.

729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Mosley Wealth Management held 47 shares of Regeneron Pharmaceuticals worth $29.3K as of Q2 2026.
Regeneron Pharmaceuticals was a new Mosley Wealth Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Mosley Wealth Management's portfolio in Q2 2026, its #296 holding.
729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Mosley Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.